cancerguard.com

February 23, 2026

What cancerguard.com is and what it’s trying to do

cancerguard.com is the consumer-facing site for the Cancerguard® test, a blood-based multi-cancer early detection (MCED) test from Exact Sciences. The site is set up mostly for patients (not clinicians) and it focuses on three things: explaining what the test is, helping you request it, and walking you through what results mean.

The headline claim you’ll see right away is that a single blood draw can help detect signals associated with over 50 cancer types and subtypes, potentially before symptoms appear. The website also positions this as “in addition to” regular screening, not a replacement for mammograms, colonoscopies, etc.

Who the site says the test is for (and who it’s not for)

The intended-use language on cancerguard.com is pretty specific. It says the test is Rx only (meaning a healthcare provider has to order it) and it’s indicated for adults ages 50–84 who have no known cancer diagnosis in the last three years.

The same page also lists important boundaries:

• It’s not indicated for screening breast and prostate cancer (so it’s not trying to replace those established screening pathways).
• It was not evaluated for detection of precancerous lesions.
• Negative doesn’t rule out cancer, positive doesn’t confirm cancer. The site repeats this idea in multiple places because it’s central to how these tests should be interpreted.

There’s also a practical caution that comes up because follow-up after a positive may involve imaging with IV contrast CT. The site says providers should think carefully before ordering for people with a history of contrast reactions, and for people who are or may become pregnant.

How the test is described as working

The “How it works” section keeps the science explanation simple: normal cells release DNA and proteins into the bloodstream, and if cancer is present, there may be “unhealthy DNA or other markers” in the blood too.

The indications page gets more concrete and says Cancerguard detects alterations in circulating tumor DNA plus tumor-associated protein levels. That matters because it’s describing a test that looks across more than one biomarker class, not just one signal.

How requesting a test works on cancerguard.com

If you click into the request flow, you’ll see two main pathways:

1. Your doctor orders it if they decide it fits your situation.
2. You can request online via telehealth, and the site names Recuro Health as the telehealth partner for that route.

The flow described is straightforward:

• A provider reviews eligibility and orders the test if appropriate.
• You complete a blood draw (doctor’s office, hospital/health system, approved lab, or sometimes at home with a visiting phlebotomist).
• The sample is analyzed by Exact Sciences Laboratories, with results typically ready in about 2 weeks.
• You review results with a clinician and decide next steps.

One other “website” detail that’s easy to miss: cancerguard.com has a patient login link that routes into Exact Sciences’ patient portal infrastructure, which signals this is meant to integrate into an existing diagnostics workflow rather than being a standalone wellness gadget.

Pricing, payment, and the consumer angle

The homepage lists a $689 self-pay price and calls the test HSA/FSA eligible (with the usual “check with your administrator” type of wording in footnotes).

The site also offers gift cards right in the header navigation. That’s unusual for medical testing, but it fits the direction the site is taking: it’s built like a consumer health product funnel, even though the test still requires a prescription and follow-up clinical care.

You’ll also see state availability messaging (for example, “be the first to know when available in New York state”). That kind of banner usually signals state-by-state constraints that can affect ordering or fulfillment.

Understanding results, and what the site tells you to do next

The “Test results” page is one of the more practical parts of the site. It explains that results are delivered as a clear negative or positive for a cancer signal, and it puts the “what now?” guidance right next to each.

For negative results, the site says “no cancer signal detected,” and claims 97% of tests will come back negative. The action plan is basically: keep up routine recommended screening and consider retesting as part of annual care.

For positive results, the site is careful: a detected signal does not mean you definitely have cancer, but it does mean additional evaluation is needed. It says providers may order imaging or other tests to try to locate and confirm cancer or to rule it out.

Two support features get emphasized for positives:

• Care Navigator support (nurse or other health professional) to help with logistics like finding locations and scheduling follow-ups.
• A potential imaging reimbursement program up to $6,000 for non-covered imaging costs, with eligibility rules and an application requirement.

The regulatory and lab-status disclosures

cancerguard.com is explicit that Cancerguard is a laboratory developed test (LDT) and that it has not been cleared or approved by the U.S. FDA. It also says the test is performed at Exact Sciences Laboratories and notes CAP accreditation and CLIA certification for high-complexity testing.

That section matters because it sets expectations: the test is commercially offered, but it’s operating under the LDT framework rather than through an FDA-cleared IVD pathway (at least as described on the site).

Key takeaways

• cancerguard.com is a patient-focused site for an Rx-only blood test intended to detect cancer signals across 50+ cancer types/subtypes, alongside—not replacing—standard screening.
• The stated indicated age range is 50–84, with no known cancer diagnosis in the prior three years.
• The site is built around a simple flow: request → blood draw options → results in about 2 weeks → review with a clinician.
• Results are framed as “signal detected” vs “no signal detected,” with clear warnings about false positives/negatives and the need for follow-up evaluation.
• It’s positioned as self-pay ($689) with HSA/FSA eligibility messaging, plus support programs (Care Navigator and possible imaging reimbursement for positive results).

FAQ

Is Cancerguard meant to replace my mammogram, colonoscopy, or other routine screening?

No. The site repeatedly frames the test as something to use in addition to routine screening, not as a substitute.

What does a positive result actually mean?

It means the blood test identified a cancer signal that may indicate cancer, but it does not confirm cancer by itself. The site says follow-up clinical evaluation and imaging are needed to locate and confirm a diagnosis or rule cancer out.

What cancers does it not screen for?

The indications page says it’s not indicated for screening breast and prostate cancer.

How do I get the test if I don’t want to start with my doctor?

The site says you can request it online through a partnered telehealth provider, Recuro Health, who reviews eligibility and can prescribe if appropriate.

How long does it take to get results?

The “How it works” and request pages say results are generally ready in about 2 weeks.